KC
KPTI icon

Kingfisher Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Kingfisher Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,539
Closed -$1.43M – 168
2020
Q3 		$1.43M Buy
6,539
+4,681
+252% +$1.14M 0.51% 77
2020
Q2 		$528K Buy
+1,858
New +$550K 0.23% 105

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Kingfisher Capital's KPTI Position: Q4 2020 in Review

Kingfisher Capital sold out of Karyopharm Therapeutics (KPTI) in Q4 2020, closing a stake of 6,539 shares — an estimated $1.43M sold.

Kingfisher Capital first reported a position in KPTI in Q2 2020 and held it in 2 quarters. The position peaked at $1.43M in Q3 2020. 168 funds tracked by Wall St. Rank hold KPTI as of Q4 2020.

  • Kingfisher Capital reported no remaining Karyopharm Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Kingfisher Capital sold 6,539 Karyopharm Therapeutics shares in Q4 2020, an estimated $1.43M.
  • Kingfisher Capital first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 2 quarters.
  • Kingfisher Capital's Karyopharm Therapeutics position peaked at $1.43M in Q3 2020.
  • 168 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2020.

Based on Kingfisher Capital's 13F filing for Q4 2020, filed 28 Jan 2021.